Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats

被引：0
|
作者：
Krasnova, M. V. [1 ]
Kulikov, A. N. [2 ]
Okovityi, S. V. [1 ]
Ivkin, D. Y. U. [1 ]
Karpov, A. A. [3 ]
Tkacheva, A. V. [1 ]
Vaulina, D. A. [2 ]
Kayukov, I. G. [2 ]
Smirnov, V. A. [2 ]
机构：
[1] St Petersburg State Chem Pharmaceut Acad, St Petersburg, Russia
[2] St Petersburg State Med Univ, St Petersburg, Russia
[3] Almazov Natl Med Res Ctr, St Petersburg, Russia
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P591
引用
收藏
页码：150 / 151
页数：2
相关论文
共 50 条
  • [41] Prognostication of post-infarct chronic heart failure: Superiority of clinical assessment vs. cardiopulmonary and left ventricular function analysis
    Nixdorff, Uwe
    Drees, Michael
    von Bardeleben, Stephan
    Mohr-Kahaly, Susanne
    Klinghammer, Lutz
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 132 (02) : 187 - 196
  • [42] Pinocembrin ameliorates post-infarct heart failure through activation of Nrf2/HO-1 signaling pathway
    Xiuhuan Chen
    Weiguo Wan
    Yan Guo
    Tianxin Ye
    Yuhong Fo
    Yazhou Sun
    Chuan Qu
    Bo Yang
    Cui Zhang
    Molecular Medicine, 2021, 27
  • [43] Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories findings from the EMPEROR-Pooled
    Butler, J.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1064 - 1064
  • [44] Post-infarct injection of an adenoviral vector expressing hepatocyte growth factor into skeletal muscle relieves ventricular remodeling and heart failure in mice
    Li, YW
    Takemura, G
    Hayakawa, K
    Kasai, K
    Nagano, S
    Yuge, K
    Esaki, M
    Koda, M
    Kawase, Y
    Maruyama, R
    Fujiwara, T
    Fujiwara, H
    CIRCULATION, 2002, 106 (19) : 30 - 31
  • [45] Acetylation of Mitochondrial Proteins Alters Fatty Acid β-Oxidation in Skeletal Muscle and Limits Exercise Capacity in Post-Infarct Heart Failure in Mice
    Tsuda, Masaya
    Fukushima, Arata
    Matsumoto, Junichi
    Takada, Shingo
    Yokota, Takashi
    Furihata, Takaaki
    Katayama, Takashi
    Nakajima, Takayuki
    Nambu, Hideo
    Maekawa, Satoshi
    Shirakawa, Ryosuke
    Kakutani, Naoya
    Obata, Yoshikuni
    Yamanashi, Katsuma
    Okita, Koichi
    Kinugawa, Shintaro
    CIRCULATION, 2017, 136
  • [46] Brain-Derived Neurotrophic Factor Regulates Exercise Capacity and Mitochondria' Function in the Skeletal Muscle in Mice with Post-Infarct Heart Failure
    Matsumoto, Junichi
    Takada, Shingo
    Kinugawa, Shintaro
    Furihata, Takaaki
    Tsuda, Masaya
    Nakajima, Takayuki
    Katayama, Takashi
    Mizushima, Wataru
    Yokota, Takashi
    Tsutsui, Hiroyuki
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S213 - S213
  • [47] Brain-derived neurotrophic factor improves exercise capacity and mitochondrial function in the skeletal muscle in mice with post-infarct heart failure
    Matsumoto, J.
    Takada, S.
    Kinugawa, S.
    Mizushima, W.
    Furihata, T.
    Tsuda, M.
    Nakajima, T.
    Katayama, T.
    Yokota, T.
    Okita, K.
    Tsutsui, H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 708 - 708
  • [48] Recombinant Elabela-Fc fusion protein has extended plasma half-life and mitigates post-infarct heart dysfunction in rats
    Wang, Yajing
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 300 : 217 - 218
  • [49] Recombinant Fc-Elabela fusion protein has extended plasma half-life andmitigates post-infarct heart dysfunction in rats
    Xi, Yue
    Yu, Daozhan
    Yang, Rongze
    Zhao, Qingbin
    Wang, Junhong
    Zhang, Hong
    Qian, Kun
    Shi, Zhengrong
    Wang, Weimin
    Brown, Robert
    Li, Yongxia
    Tian, Zhenjun
    Gong, Da-Wei
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 292 : 180 - 187
  • [50] Comparative Efficacy Between Dapagliflozin And Empagliflozin On Symptoms And Functional Capacity In Patients With Heart Failure: A Network Meta-analysis
    Addo, Basilio
    Ibrahim, Sammudeen
    Akpan, Inemesit
    Ansari, Fawwad
    Allihien, Saint-martin
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
12345